<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cell Therapy on FinanClub</title>
    <link>https://finan.club/tags/cell-therapy/</link>
    <description>Recent content in Cell Therapy on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 13 Mar 2024 09:07:26 +0000</lastBuildDate><atom:link href="https://finan.club/tags/cell-therapy/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IOVA</title>
      <link>https://finan.club/us/iova/</link>
      <pubDate>Wed, 13 Mar 2024 09:07:26 +0000</pubDate>
      
      <guid>https://finan.club/us/iova/</guid>
      <description>score:-12
Chances: Iovance Biotherapeutics&amp;rsquo; revenue is set to grow, indicating potential for increased stock value. The FDA has lifted a partial clinical hold on Iovance&amp;rsquo;s mid-stage study, showing positive regulatory progress. Risks: Iovance Biotherapeutics reported a net loss of $116.4 million in Q4, reflecting financial risk and potential impact on stock performance.</description>
    </item>
    
    <item>
      <title>SANA</title>
      <link>https://finan.club/us/sana/</link>
      <pubDate>Sat, 02 Mar 2024 09:02:41 +0000</pubDate>
      
      <guid>https://finan.club/us/sana/</guid>
      <description>score:46
Chances: Sana Biotechnology has successfully cleared IND for B-cell mediated autoimmune diseases with initial clinical data expected in 2024 Early data from ongoing ARDENT trial suggests the ability to dose safely, demonstrate the desired immune evasion profile, and early clinical efficacy Risks: Markets are awaiting the latest inflation numbers and the debate regarding soft vs hard landing is expected to persist on Wall Street High institutional ownership implies Sana Biotechnology&amp;rsquo;s stock price is sensitive to their decisions Score:46 chances characters count - risks characters count = 46</description>
    </item>
    
  </channel>
</rss>
